Ege University

In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes.
\n
\nFor example, a key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process versus those that measure flux through the autophagy pathway (i.e., the complete process including the amount and rate of cargo sequestered and degraded). In particular, a block in macroautophagy that results in autophagosome accumulation must be differentiated from stimuli that increase autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. It is worth emphasizing here that lysosomal digestion is a stage of autophagy and evaluating its competence is a crucial part of the evaluation of autophagic flux, or complete autophagy.
\n
\nHere, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. Along these lines, because of the potential for pleiotropic effects due to blocking autophagy through genetic manipulation, it is imperative to target by gene knockout or RNA interference more than one autophagy-related protein. In addition, some individual Atg proteins, or groups of proteins, are involved in other cellular pathways implying that not all Atg proteins can be used as a specific marker for an autophagic process. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular assays, we hope to encourage technical innovation in the field.

Simulated gastro-intestinal digestion is widely employed in many fields of food and nutritional sciences, as conducting human trials are often costly, resource intensive, and ethically disputable. As a consequence, in vitro alternatives that determine endpoints such as the bioaccessibility of nutrients and non-nutrients or the digestibility of macronutrients (e.g. lipids, proteins and carbohydrates) are used for screening and building new hypotheses. Various digestion models have been proposed, often impeding the possibility to compare results across research teams. For example, a large variety of enzymes from different sources such as of porcine, rabbit or human origin have been used, differing in their activity and characterization. Differences in pH, mineral type, ionic strength and digestion time, which alter enzyme activity and other phenomena, may also considerably alter results. Other parameters such as the presence of phospholipids, individual enzymes such as gastric lipase and digestive emulsifiers vs. their mixtures (e.g. pancreatin and bile salts), and the ratio of food bolus to digestive fluids, have also been discussed at length. In the present consensus paper, within the COST Infogest network, we propose a general standardised and practical static digestion method based on physiologically relevant conditions that can be applied for various endpoints, which may be amended to accommodate further specific requirements. A frameset of parameters including the oral, gastric and small intestinal digestion are outlined and their relevance discussed in relation to available in vivo data and enzymes. This consensus paper will give a detailed protocol and a line-by-line, guidance, recommendations and justifications but also limitation of the proposed model. This harmonised static, in vitro digestion method for food should aid the production of more comparable data in the future.

Developing a mechanistic understanding of the impact of food structure and composition on human health has increasingly involved simulating digestion in the upper gastrointestinal tract. These simulations have used a wide range of different conditions that often have very little physiological relevance, and this impedes the meaningful comparison of results. The standardized protocol presented here is based on an international consensus developed by the COST INFOGEST network. The method is designed to be used with standard laboratory equipment and requires limited experience to encourage a wide range of researchers to adopt it. It is a static digestion method that uses constant ratios of meal to digestive fluids and a constant pH for each step of digestion. This makes the method simple to use but not suitable for simulating digestion kinetics. Using this method, food samples are subjected to sequential oral, gastric and intestinal digestion while parameters such as electrolytes, enzymes, bile, dilution, pH and time of digestion are based on available physiological data. This amended and improved digestion method (INFOGEST 2.0) avoids challenges associated with the original method, such as the inclusion of the oral phase and the use of gastric lipase. The method can be used to assess the endpoints resulting from digestion of foods by analyzing the digestion products (e.g., peptides/amino acids, fatty acids, simple sugars) and evaluating the release of micronutrients from the food matrix. The whole protocol can be completed in ~7 d, including ~5 d required for the determination of enzyme activities.

BACKGROUND: Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease. METHODS: In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of intravenous temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) subcutaneously three times weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa three times weekly. The primary end point was overall survival in comparisons of the temsirolimus group and the combination-therapy group with the interferon group. RESULTS: Patients who received temsirolimus alone had longer overall survival (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P=0.008) and progression-free survival (P<0.001) than did patients who received interferon alone. Overall survival in the combination-therapy group did not differ significantly from that in the interferon group (hazard ratio, 0.96; 95% CI, 0.76 to 1.20; P=0.70). Median overall survival times in the interferon group, the temsirolimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 months, respectively. Rash, peripheral edema, hyperglycemia, and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in the interferon group. There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02). CONCLUSIONS: As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov].).

A new periodontitis classification scheme has been adopted, in which forms of the disease previously recognized as "chronic" or "aggressive" are now grouped under a single category ("periodontitis") and are further characterized based on a multi-dimensional staging and grading system. Staging is largely dependent upon the severity of disease at presentation as well as on the complexity of disease management, while grading provides supplemental information about biological features of the disease including a history-based analysis of the rate of periodontitis progression; assessment of the risk for further progression; analysis of possible poor outcomes of treatment; and assessment of the risk that the disease or its treatment may negatively affect the general health of the patient. Necrotizing periodontal diseases, whose characteristic clinical phenotype includes typical features (papilla necrosis, bleeding, and pain) and are associated with host immune response impairments, remain a distinct periodontitis category. Endodontic-periodontal lesions, defined by a pathological communication between the pulpal and periodontal tissues at a given tooth, occur in either an acute or a chronic form, and are classified according to signs and symptoms that have direct impact on their prognosis and treatment. Periodontal abscesses are defined as acute lesions characterized by localized accumulation of pus within the gingival wall of the periodontal pocket/sulcus, rapid tissue destruction and are associated with risk for systemic dissemination.

autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.

BACKGROUND & AIMS: Although functional gastrointestinal disorders (FGIDs), now called disorders of gut-brain interaction, have major economic effects on health care systems and adversely affect quality of life, little is known about their global prevalence and distribution. We investigated the prevalence of and factors associated with 22 FGIDs, in 33 countries on 6 continents. METHODS: Data were collected via the Internet in 24 countries, personal interviews in 7 countries, and both in 2 countries, using the Rome IV diagnostic questionnaire, Rome III irritable bowel syndrome questions, and 80 items to identify variables associated with FGIDs. Data collection methods differed for Internet and household groups, so data analyses were conducted and reported separately. RESULTS: Among the 73,076 adult respondents (49.5% women), diagnostic criteria were met for at least 1 FGID by 40.3% persons who completed the Internet surveys (95% confidence interval [CI], 39.9-40.7) and 20.7% of persons who completed the household surveys (95% CI, 20.2-21.3). FGIDs were more prevalent among women than men, based on responses to the Internet survey (odds ratio, 1.7; 95% CI, 1.6-1.7) and household survey (odds ratio, 1.3; 95% CI, 1.3-1.4). FGIDs were associated with lower quality of life and more frequent doctor visits. Proportions of subjects with irritable bowel syndrome were lower when the Rome IV criteria were used, compared with the Rome III criteria, in the Internet survey (4.1% vs 10.1%) and household survey (1.5% vs 3.5%). CONCLUSIONS: In a large-scale multinational study, we found that more than 40% of persons worldwide have FGIDs, which affect quality of life and health care use. Although the absolute prevalence was higher among Internet respondents, similar trends and relative distributions were found in people who completed Internet vs personal interviews.

A new periodontitis classification scheme has been adopted, in which forms of the disease previously recognized as "chronic" or "aggressive" are now grouped under a single category ("periodontitis") and are further characterized based on a multi-dimensional staging and grading system. Staging is largely dependent upon the severity of disease at presentation as well as on the complexity of disease management, while grading provides supplemental information about biological features of the disease including a history-based analysis of the rate of periodontitis progression; assessment of the risk for further progression; analysis of possible poor outcomes of treatment; and assessment of the risk that the disease or its treatment may negatively affect the general health of the patient. Necrotizing periodontal diseases, whose characteristic clinical phenotype includes typical features (papilla necrosis, bleeding, and pain) and are associated with host immune response impairments, remain a distinct periodontitis category. Endodontic-periodontal lesions, defined by a pathological communication between the pulpal and periodontal tissues at a given tooth, occur in either an acute or a chronic form, and are classified according to signs and symptoms that have direct impact on their prognosis and treatment. Periodontal abscesses are defined as acute lesions characterized by localized accumulation of pus within the gingival wall of the periodontal pocket/sulcus, rapid tissue destruction and are associated with risk for systemic dissemination.

BACKGROUND: In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS; the number of PD-L1-staining tumor cells, lymphocytes, and macrophages, divided by the total number of viable tumor cells, multiplied by 100) of 10 or more. The results of the final analysis of overall survival have not been reported. METHODS: We randomly assigned patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in a 2:1 ratio to receive pembrolizumab (200 mg) every 3 weeks plus the investigator's choice of chemotherapy (nanoparticle albumin-bound paclitaxel, paclitaxel, or gemcitabine-carboplatin) or placebo plus chemotherapy. The primary end points were progression-free survival (reported previously) and overall survival among patients whose tumors expressed PD-L1 with a CPS of 10 or more (the CPS-10 subgroup), among patients whose tumors expressed PD-L1 with a CPS of 1 or more (the CPS-1 subgroup), and in the intention-to-treat population. Safety was also assessed. RESULTS: A total of 847 patients underwent randomization: 566 were assigned to the pembrolizumab-chemotherapy group, and 281 to the placebo-chemotherapy group. The median follow-up was 44.1 months. In the CPS-10 subgroup, the median overall survival was 23.0 months in the pembrolizumab-chemotherapy group and 16.1 months in the placebo-chemotherapy group (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.55 to 0.95; two-sided P = 0.0185 [criterion for significance met]); in the CPS-1 subgroup, the median overall survival was 17.6 and 16.0 months in the two groups, respectively (hazard ratio, 0.86; 95% CI, 0.72 to 1.04; two-sided P = 0.1125 [not significant]); and in the intention-to-treat population, the median overall survival was 17.2 and 15.5 months, respectively (hazard ratio, 0.89; 95% CI, 0.76 to 1.05 [significance not tested]). Adverse events of grade 3, 4, or 5 that were related to the trial regimen occurred in 68.1% of the patients in the pembrolizumab-chemotherapy group and in 66.9% in the placebo-chemotherapy group, including death in 0.4% of the patients in the pembrolizumab-chemotherapy group and in no patients in the placebo-chemotherapy group. CONCLUSIONS: Among patients with advanced triple-negative breast cancer whose tumors expressed PD-L1 with a CPS of 10 or more, the addition of pembrolizumab to chemotherapy resulted in significantly longer overall survival than chemotherapy alone. (Funded by Merck Sharp and Dohme; KEYNOTE-355 ClinicalTrials.gov number, NCT02819518.).

This paper is the outcome of a community initiative to identify major unsolved scientific problems in hydrology motivated by a need for stronger harmonisation of research efforts. The procedure involved a public consultation through online media, followed by two workshops through which a large number of potential science questions were collated, prioritised, and synthesised. In spite of the diversity of the participants (230 scientists in total), the process revealed much about community priorities and the state of our science: a preference for continuity in research questions rather than radical departures or redirections from past and current work. Questions remain focused on the process-based understanding of hydrological variability and causality at all space and time scales. Increased attention to environmental change drives a new emphasis on understanding how change propagates across interfaces within the hydrological system and across disciplinary boundaries. In particular, the expansion of the human footprint raises a new set of questions related to human interactions with nature and water cycle feedbacks in the context of complex water management problems. We hope that this reflection and synthesis of the 23 unsolved problems in hydrology will help guide research efforts for some years to come.

Chicago Classification v4.0 (CCv4.0) is the updated classification scheme for esophageal motility disorders using metrics from high-resolution manometry (HRM). Fifty-two diverse international experts separated into seven working subgroups utilized formal validated methodologies over two-years to develop CCv4.0. Key updates in CCv.4.0 consist of a more rigorous and expansive HRM protocol that incorporates supine and upright test positions as well as provocative testing, a refined definition of esophagogastric junction (EGJ) outflow obstruction (EGJOO), more stringent diagnostic criteria for ineffective esophageal motility and description of baseline EGJ metrics. Further, the CCv4.0 sought to define motility disorder diagnoses as conclusive and inconclusive based on associated symptoms, and findings on provocative testing as well as supportive testing with barium esophagram with tablet and/or functional lumen imaging probe. These changes attempt to minimize ambiguity in prior iterations of Chicago Classification and provide more standardized and rigorous criteria for patterns of disorders of peristalsis and obstruction at the EGJ.

In response to the 2013 Update of the European Strategy for Particle Physics, the Future Circular Collider (FCC) study was launched, as an international collaboration hosted by CERN. This study covers a highest-luminosity high-energy lepton collider (FCC-ee) and an energy-frontier hadron collider (FCC-hh), which could, successively, be installed in the same 100 km tunnel. The scientific capabilities of the integrated FCC programme would serve the worldwide community throughout the 21st century. The FCC study also investigates an LHC energy upgrade, using FCC-hh technology. This document constitutes the second volume of the FCC Conceptual Design Report, devoted to the electron-positron collider FCC-ee. After summarizing the physics discovery opportunities, it presents the accelerator design, performance reach, a staged operation scenario, the underlying technologies, civil engineering, technical infrastructure, and an implementation plan. FCC-ee can be built with today’s technology. Most of the FCC-ee infrastructure could be reused for FCC-hh. Combining concepts from past and present lepton colliders and adding a few novel elements, the FCC-ee design promises outstandingly high luminosity. This will make the FCC-ee a unique precision instrument to study the heaviest known particles (Z, W and H bosons and the top quark), offering great direct and indirect sensitivity to new physics.

This article updates the Heart Failure Association of the European Society of Cardiology (ESC) 2007 classification of advanced heart failure and describes new diagnostic and treatment options for these patients. Recognizing the patient with advanced heart failure is critical to facilitate timely referral to advanced heart failure centres. Unplanned visits for heart failure decompensation, malignant arrhythmias, co-morbidities, and the 2016 ESC guidelines criteria for the diagnosis of heart failure with preserved ejection fraction are included in this updated definition. Standard treatment is, by definition, insufficient in these patients. Inotropic therapy may be used as a bridge strategy, but it is only a palliative measure when used on its own, because of the lack of outcomes data. Major progress has occurred with short-term mechanical circulatory support devices for immediate management of cardiogenic shock and long-term mechanical circulatory support for either a bridge to transplantation or as destination therapy. Heart transplantation remains the treatment of choice for patients without contraindications. Some patients will not be candidates for advanced heart failure therapies. For these patients, who are often elderly with multiple co-morbidities, management of advanced heart failure to reduce symptoms and improve quality of life should be emphasized. Robust evidence from prospective studies is lacking for most therapies for advanced heart failure. There is an urgent need to develop evidence-based treatment algorithms to prolong life when possible and in accordance with patient preferences, increase life quality, and reduce the burden of hospitalization in this vulnerable patient population.

Drought stress, which causes a decline in quality and quantity of crop yields, has become more accentuated these days due to climatic change. Serious measures need to be taken to increase the tolerance of crop plants to acute drought conditions likely to occur due to global warming. Drought stress causes many physiological and biochemical changes in plants, rendering the maintenance of osmotic adjustment highly crucial. The degree of plant resistance to drought varies with plant species and cultivars, phenological stages of the plant, and the duration of plant exposure to the stress. Osmoregulation in plants under low water potential relies on synthesis and accumulation of osmoprotectants or osmolytes such as soluble proteins, sugars, and sugar alcohols, quaternary ammonium compounds, and amino acids, like proline. This review highlights the role of osmolytes in water-stressed plants and of enzymes entailed in their metabolism. It will be useful, especially for researchers working on the development of drought-resistant crops by using the metabolic-engineering techniques.

Abstract Systematic assessments of species extinction risk at regular intervals are necessary for informing conservation action 1,2 . Ongoing developments in taxonomy, threatening processes and research further underscore the need for reassessment 3,4 . Here we report the findings of the second Global Amphibian Assessment, evaluating 8,011 species for the International Union for Conservation of Nature Red List of Threatened Species. We find that amphibians are the most threatened vertebrate class (40.7% of species are globally threatened). The updated Red List Index shows that the status of amphibians is deteriorating globally, particularly for salamanders and in the Neotropics. Disease and habitat loss drove 91% of status deteriorations between 1980 and 2004. Ongoing and projected climate change effects are now of increasing concern, driving 39% of status deteriorations since 2004, followed by habitat loss (37%). Although signs of species recoveries incentivize immediate conservation action, scaled-up investment is urgently needed to reverse the current trends.

Abstract The grand challenges of contemporary fundamental physics—dark matter, dark energy, vacuum energy, inflation and early universe cosmology, singularities and the hierarchy problem—all involve gravity as a key component. And of all gravitational phenomena, black holes stand out in their elegant simplicity, while harbouring some of the most remarkable predictions of General Relativity: event horizons, singularities and ergoregions. The hitherto invisible landscape of the gravitational Universe is being unveiled before our eyes: the historical direct detection of gravitational waves by the LIGO-Virgo collaboration marks the dawn of a new era of scientific exploration. Gravitational-wave astronomy will allow us to test models of black hole formation, growth and evolution, as well as models of gravitational-wave generation and propagation. It will provide evidence for event horizons and ergoregions, test the theory of General Relativity itself, and may reveal the existence of new fundamental fields. The synthesis of these results has the potential to radically reshape our understanding of the cosmos and of the laws of Nature. The purpose of this work is to present a concise, yet comprehensive overview of the state of the art in the relevant fields of research, summarize important open problems, and lay out a roadmap for future progress. This write-up is an initiative taken within the framework of the European Action on ‘Black holes, Gravitational waves and Fundamental Physics’.

A good understanding of the mechanisms and magnitude of impact of invasive alien species on ecosystem services and biodiversity is a prerequisite for efficient prioritization of actions for prevention of new invasions or for mitigation measures. In this review, we have identified marine alien species of high-impact on ecosystem services and biodiversity in the European seas, classified the mechanisms of impact, commented on the methods applied for assessing impact and the related inferential strength, and reported gaps in available information. Furthermore, we have proposed an updated inventory of 86 marine species in Europe, representing 12 phyla, with documented high impact on ecosystem services or biodiversity. \nFood provision was the ecosystem service that was impacted by the highest number of alien species (in terms of both positive and negative impacts). Following food provision, the ecosystem services that were negatively affected by the highest number of species were ocean nourishment, recreation and tourism, and water purification, while the ecosystem services that were more often positively impacted were water purification, cognitive benefits, and climate regulation. In many cases, marine aliens impact keystone/protected species and habitats. Almost 30% of the assessed species affected entire ecosystem processes or wider ecosystem function, more often in a negative way. Fifty of the assessed species have been reported to be ecosystem engineers, fundamentally modifying, creating or defining habitats by altering their physical or chemical properties.\nPositive impacts of alien species are probably underestimated, as there is a persistent perception bias against alien species. We conclude that the “native good, alien bad” philosophy is a misconception and the role of most of the alien species in marine ecosystems is rather complex. Among the species herein assessed as high-impact species, 15 had only negative and 8 only positive impacts; for the majority (64 species) both negative and positive impacts have been reported, and the overall balance is often unknown. Although there is no doubt that invasive species have modified marine ecosystems, evidence for most of the reported impacts is weak, as it is based on expert judgement or dubious correlations, while only ~10% of the reported impacts were inferred via manipulative or natural experiments. A need for stronger inference is evident, to improve our knowledge base of marine biological invasions and better inform managers.

Nutritional status should be assessed at the start of haemodialysis (Opinion). Protein–energy malnutrition should be avoided in maintenance haemodialysis because of poor patient outcome (Evidence III). In absence of malnutrition, nutritional status should be monitored every 6 months in patients <50 years of age (Opinion). In patients >50 years of age, and patients undergoing maintenance dialysis for more than 5 years, nutritional status should be monitored every 3 months (Opinion). Malnutrition is considered to be one of the late complications of chronic renal failure. A sub-analysis of the Modification of Diet in Renal Disease (MDRD) study, however, demonstrated that progressive renal insufficiency was associated with a spontaneous decline in protein intake. Predialysis patients appeared to have a spontaneous protein intake of <0.7 g/kg/day [1], which is below the minimal recommended daily intake. Thus, malnutrition in haemodialysis patients may already originate during stage IV of chronic renal failure. It has been demonstrated that serum albumin and creatinine increase during the first half year of haemodialysis [2,3], suggesting an improvement of nutritional status after the initiation of dialysis. Nevertheless, many studies have reported on the presence of malnutrition in a large number of dialysis patients [4–7]. In the French national cooperative study [6], that included 7123 patients, nutritional status was determined by body mass index (BMI), normalized protein catabolic rate (nPCR) and several laboratory values. Life-threatening malnutrition was present in up to 36% of the patients. Low protein intake and low dialysis efficacy were associated with the presence of malnutrition. Several other studies demonstrated that haemodialysis patients eat less protein and fewer calories than prescribed, which is associated with a higher rate of malnutrition [4,5,7]. Several small and large scale cohort studies have revealed that protein–energy malnutrition is associated with increased morbidity, mortality and impaired quality of life [8–19]. Herselman et al . [10] demonstrated an association between a composite score for protein–energy malnutrition and infection-related morbidity in a group of haemodialysis patients. A recent paper demonstrated that in patients with an appropriate dialysis efficacy (Kt/V ≥ 1.2) low serum albumin and low protein intake, measured as low nPCR, were associated with a higher risk of hospitalization and mortality [17]. Data from the United States Renal Data System (USRDS) database [13] as well as data from the large Dialysis Outcomes and Practice Patterns Study (DOPPS) cohort [14] confirm that malnourished dialysis patients have an increased risk of mortality. In the USRDS DMMS-1 cohort analysis protein–energy malnutrition was established through serum albumin levels, BMI and notification by the treating physicians in the patient medical files of the existence of malnutrition [13]. From this data set of 5058 patients it was concluded that patients who were considered malnourished by their physicians, had a 27% greater risk of cardiovascular death. In addition it was shown that for each one-unit decrease in BMI the risk for cardiovascular death rose by 6% and each 1 g/dl fall in serum albumin level was associated with a 39% increase in risk of cardiovascular death. A recent study reported that both malnutrition, established by measurement of total body nitrogen by in vivo neutron activation analysis, and serum albumin were independent predictors of mortality in incident haemodialysis patients [19]. Hypoalbuminaemia appeared also to be a predictor of vascular morbidity. In DOPPS, a prospective observational study, nutritional status is investigated by means of a modified subjective global assessment (mSGA), BMI, serum albumin and some other laboratory parameters at baseline ( n = 7719) and after 6 months ( n = 3739; [14]). Patients with severe malnutrition according to mSGA had a 33% higher mortality risk and patients with moderate malnutrition a 5% increased risk. In patients with the lowest BMI quartile the mortality risk was 60% higher than that of patients in the highest quartile. In addition it was demonstrated that patients who had a loss in BMI of ⩾3.5% had an increase in mortality risk. Likewise, both a low serum albumin level as well as a fall in serum albumin was strongly associated with an elevated mortality risk. Apart from the elevated risk of mortality, from the study have revealed that malnutrition, established with serum albumin and was associated with impaired and impaired quality of life Likewise, et al . reported an association between and malnutrition in a group of chronic haemodialysis patients. It is that age outcome of dialysis patients. It has been demonstrated in a studies that malnutrition to the increased mortality risk of dialysis patients In the study, it was demonstrated that age and dialysis patients had and protein intake, serum albumin and with dialysis patients dialysis efficacy measured as for malnutrition in the patients were associated with higher morbidity. In a French cohort study, it was shown that in dialysis patients years, malnutrition dialysis In several small and studies dialysis appeared to have a on nutritional status of dialysis patients In a cohort study of patients, et al . were to that dialysis was associated with a decline in nutritional parameters and that every year on dialysis was associated with a 6% increase in the risk of Likewise, in the study it was shown that patients 5 years on dialysis had parameters suggesting an impaired nutritional status with patients on dialysis was also shown in studies with more for of nutritional status an of nutritional status is an of haemodialysis patients and for the of body associated with increased protein intake during of chronic renal failure. in serum albumin and creatinine in the first half year on et al . in patients on a low protein and nutritional in maintenance patients. of nutritional status of the Dialysis Study et al . Nutritional status of haemodialysis a French national cooperative French Study for in Study on nutritional status of maintenance patients. nutritional as independent predictors of mortality in patients. albumin is a predictor of death in chronic dialysis patients. Herselman Protein–energy malnutrition as a risk for increased morbidity in patients. Renal et al . of nutritional with and status in patients from the Renal et al . Nutritional status quality of life in Study patients at Renal et al . risk for cardiovascular mortality malnourished renal patients et al . risk in patients and in nutritional association of with nutritional parameters and mortality risk in patients. Renal et al . Nutritional status assessed from in the Renal protein nitrogen is with hospitalization and mortality in patients with greater than Renal et al . of with malnutrition in chronic patients. malnutrition and as predictors of vascular and mortality in of subjective global assessment as a nutritional in renal et al . between protein and intake, nutritional and in patients. Renal et al . in patients than outcome of on nutritional status in patients with renal failure. et al . body nitrogen as a in maintenance dialysis. et al . as nutritional risk for the of patients. et al . for nutritional assessment of dialysis patients. nutritional and in patients et al . Nutritional status in and dialysis. study of nutritional body and in patients Protein–energy malnutrition and predictors of death haemodialysis patients. is a measurement that and assessment of the nutritional status of haemodialysis patients below a nutritional should it should also be an and that is by as age and nutritional is at the of a of and that with nutritional status is to protein–energy malnutrition in a and in the of in and and patients to their to a that for maintenance haemodialysis on also nutritional as and patients have nutritional and to It is to their as as 1 should be in and should be in the It is to and after a as patients should be every 3 6 months according to age years, every 6 >50 years every 3 and dialysis years, every 6 years every 3 as to patients and patients should be assessed and at for and be to as Malnutrition should be by a number of assessment assessment mass index global assessment albumin and serum haemodialysis patient should have to a (Opinion). haemodialysis patients should a and in the and should be on medical and (Opinion). haemodialysis patients should be and 1 after haemodialysis has (Opinion). haemodialysis patients should be and more (Opinion). intake should be during a of 3 and should a dialysis and a (Evidence level III). of intake be by to intake of patients from to 3 and the of a is to and as to intake, and of a set of the nutritional status of patients on Data from and a of should be with as be subjective and Patients may their intake is poor their intake is of in be by a a patient as and during the is a that a of and may be in the in patients on It of which It is a for more and on and patients may intake. intake during the may be for the from is to a and may a intake daily may as patients less and several of may more to protein and intake. In patients with a intake a of may be to protein and intake. Disease Outcomes for Nutritional a which a dialysis a and a a A is as patients with for a to of Patients should be to and A the and and a of the of in and the of and A of is to protein and intake to of may be to intake from as as to the of a is that in intake a In to protein catabolic rate protein intake and intake et al . that a with the of and protein and intake with a measurement during the protein and intake from to as a of dialysis and associated in intake. In this study, patients to to intake. Patients were also their A be in addition to to intake in a large number of patients during a In the recent Study patients at during an a dialysis after from years assessed was with the and Diet to in and on both dialysis and nutritional intake was also is to the of the in to and in and In study an and was by et al . to intake in a small number of patients on chronic were to nutritional intake. Dialysis and data and were also between and protein–energy by was was to be and be as a to poor and that to malnutrition. patients should a BMI (Evidence level BMI is to the outcome of BMI is on and mass and total body a of be of and more in the of loss a of BMI it should be that a higher of mass is in and body and a higher of mass in less and patients. Several studies have shown that a BMI of and higher the risk of morbidity and mortality BMI and with age and dialysis in and patients In a analysis, et al . investigated the between BMI and the rate of mortality in patients. BMI was and the age of patients was and and with were with of patients in and were in age and that death in patients with a BMI in the the and were higher with with a BMI in the a improvement in death with study also that age was strongly associated with of death with BMI is a predictor of mortality in patients a and that is an independent predictor of mortality in patients below the with a BMI of at for and for Data from a cohort of patients of the French Study in Dialysis that and patients with a BMI of and albumin had an increased rate of at 1 year and at years From the Study of the USRDS with a national of patients with a age of years, et al . [10] concluded that BMI at baseline was a independent predictor of mortality risk and 5 years prospective baseline and BMI data on patients in and during analysis was to the between BMI and risk of mortality in patients by of in on a score from and serum albumin age and and a in the of mortality as BMI increased and this was for patients in the age group of years who were also in the of A BMI of was associated with the highest mortality risk et al . also concluded that a higher BMI was associated with in cohort patients on with a of 5 years, in a study of the USRDS and Study that patients with a BMI had a of for patients with a BMI and this was ( = should be to severe malnutrition in haemodialysis patients (Evidence level III). is on a of subjective and from the medical and A modified of the has been in the States Dialysis Study and studies It was demonstrated that of the mSGA were associated with a higher mortality risk concluded that in haemodialysis patients malnutrition, as by low with the was associated with higher mortality risk In a prospective observational study, it was also shown that patients with the lowest score had higher mortality and hospitalization [17]. In a with the of body nitrogen by means of in vivo neutron activation analysis it was demonstrated that was to malnourished patients from with appeared to be a predictor of the of malnutrition in patients should be assessed after dialysis (Opinion). and should be by the on the (Opinion). BMI, and to and body mass and may a risk for and to and to nutritional status of patients on status and for nutritional and is to It is to at to an assessment of total body and and and to body mass and body from for and analysis et al . body body mass body and total body and in patients and a between the ( = and that be the as is and minimal to et al . also that were with and for body patients were body and were and is recommended to for body assessment that to in the of patients. should be measured in haemodialysis patients and be (Evidence level an independent and less assessment of protein intake. the between intake and is in the protein and protein strongly by body In to it should be to body of the patients should be and catabolic protein of total be from in nitrogen in serum and A recent study in more than haemodialysis patients reported that mortality was lowest for patients a between and patients had a after a the mortality increased should be to nutritional as one of several independent nutritional albumin should be by (Evidence level III). other albumin assessment the should be to the (Opinion). should be (Evidence level albumin is recommended for measurement because a large body of is that serum albumin and the serum albumin is an of protein recent years the between and malnutrition status as and protein intake on serum albumin A number of the between serum albumin and outcome Hypoalbuminaemia is a predictor of mortality and at the of initiation of dialysis and at during dialysis patients in the study, in the low albumin group had greater of albumin should fall below by the Patients with a serum albumin level below have a mortality risk of a of as with a of in with a serum albumin greater than albumin by poor and protein intake, also by other catabolic and age, and albumin is during the presence of chronic the of serum albumin as a nutritional of serum albumin is to and more than for serum albumin in should be to is in to in between on the national that also may have the of nutritional was for serum more of is of of is a more for the status than albumin to half life strongly with serum albumin and have shown to independent of albumin albumin is by as more than is a of protein half life of serum is of for albumin than a mortality risk of patients rate was with a serum level and in patients with a level cohort of patients for years demonstrated that each increase in serum at was associated with a decrease in the risk of death total should be measured and be the minimal laboratory (Evidence level III). is a of the recommended for to the cardiovascular risk of a haemodialysis patient Low serum of increased mortality risk is associated with chronic protein–energy the presence of with serum should be investigated for nutritional as well as for other between serum and outcome has been as with risk for mortality as serum below Low of by and by the that other nutritional serum Predialysis serum with serum creatinine and age a patient should be in the total values. the assessment of malnutrition several as analysis body and in vivo neutron activation In addition the presence of malnutrition be investigated by means of subjective global In vivo neutron activation analysis is considered the for the of protein In a and study, et al . demonstrated that haemodialysis patients a total body nitrogen suggesting protein was by et al in a group that nitrogen were more in than in studies demonstrated that a of haemodialysis patients had total body nitrogen as a nitrogen index the of measured nitrogen the nitrogen for and to be the in patients and patients dialysis late at low of renal et al . demonstrated that patients with a nitrogen index of had a risk of of with patients with a higher index et al . a of mortality of of decline in nitrogen Several studies demonstrated that with in vivo neutron activation analysis, nutritional analysis by means of the presence of protein malnutrition in haemodialysis patients in vivo neutron activation analysis with in a mass and mass and from which body is Thus, protein–energy nutritional status be data body of haemodialysis patients with that of et al . demonstrated that in with patients on chronic haemodialysis have a in In this study, the also in mass with which were with Data nutritional status between haemodialysis patients and determined with et al . demonstrated with a decrease in body mass in haemodialysis patients with et al . an index with which in a small group of haemodialysis patients that mass and body mass were in of patients with the from the suggesting the existence of malnutrition in patients. Likewise, et al . demonstrated that haemodialysis patients after haemodialysis had body and a with concluded that were in body mass that was strongly to patient Likewise, et al . in patients with chronic renal with with and with suggesting that the is the of the assessment of nutritional by means of in vivo neutron activation analysis and of in the to in a intake other malnutrition parameters start on a a of intake should be and be in the the be Patients may to be Patients may to the more to of their in their may the for a to and patients to more Nutritional status should be the assessment serum albumin and serum of other should be to (Opinion). and haemodialysis patients should be by a every months every 3 months years of age on haemodialysis for more than 5 years (Evidence level III). haemodialysis patients should at a more (Opinion). for more in patients years of age and by haemodialysis for more than 5 years have been in dialysis body should be the and in the of the should be (Opinion). should be on (Evidence level III). It has been that patients should have been on for as this more body is the on a of that the lowest morbidity and mortality may to be in and patients. loss during the months is more as a risk for protein–energy malnutrition than loss may be according to the of and Malnutrition as in 1 of loss of loss a of loss during the months be recommended for the of malnutrition. patients to between and for daily intake from to in addition to daily is on intake and a intake to and may be the of intake patients be to their daily intake to patients well also in between dialysis and this is to the of A of as as and this to the daily intake. It has been by et al . that nutritional intake. In a study of patients, a between and was a higher protein intake was associated with a higher by a analysis that and were independent ( = was a small association between and serum albumin g/dl ( in patients with a and et al . also that protein and intake was higher in patients with a higher of during the 3 and intake were assessed from from patients, for each patient for 1 study that a may be a of protein and intake and that the of was to in patients. patients of more in between dialysis and this may their nutritional intake. Nutritional is and should which patients eat well with who and have a Patients with large should be to is and should be of this with and intake of less as this may be for some patients. A of body of in patients with an nutritional intake and studies to an for the well and is for and patients. serum albumin and serum should be measured at 1 after of haemodialysis and in patients (Opinion). In patients with a number of during of and during the of should be increased to (Opinion). also several which present in patients, and and as well as serum albumin is a for nutritional status in patients. Hypoalbuminaemia in patients protein–energy malnutrition, which also may with in other nutritional is a of protein intake, is well and to in the It is to protein intake in patients. as well as of protein intake the protein intake is to protein to body be in and patients. It is recommended that for who of body the body is total is of the measured in according to in status and during for serum as for serum may with in also with in other nutritional parameters with to an in body nutritional status be monitored with several the number of studies is and of with a means of in vivo neutron activation analysis a in the nitrogen index was after 1 year in haemodialysis patients the nitrogen index with intake et al . investigated nutritional parameters for 1 year in incident haemodialysis patients every 3 months and at the and of the mass as well as mass increased suggesting an improvement of nutritional was associated with a in body mass of patients, which was by a decrease in total body In chronic haemodialysis patients a decrease in mass was after 1 year of which was to impaired nutritional status in patients From studies it be concluded that be to in body however, should which is the one and with it should be for of Renal Renal Practice Diet for in chronic renal failure. of nutritional status of the Dialysis Study of Diet dialysis and intake in the et al . of intake, and on dialysis and in From the Renal et al . of intake in a and mortality in maintenance patients. et al . Nutritional status of haemodialysis a French national cooperative French Study for in nutritional as independent predictors of mortality in patients. mass index and mortality in as with haemodialysis from the Dialysis Outcomes and Practice Patterns Study et al . mass dialysis and analysis of the United States Renal Data System Dialysis and et al . in patients than outcome et al . Nutritional status assessed from in the Renal et al . of nutritional and on the of French patients. et al . risk in patients and in nutritional quality of life and and mortality in of subjective global assessment as a nutritional in renal body analysis in nutritional status of patients on maintenance which is to be in patient of for the of body in patients on Diet et al . A for dialysis et al . between protein intake and in patients. and protein intake on serum albumin and creatinine in patients. et al . nutritional status associated with mortality in the risk in the of measured and an of death rate between is a predictor of death in a cohort of chronic patients. morbidity, and mortality in renal and serum albumin as predictors of mortality in patients undergoing protein as an outcome predictor for maintenance patients. et al . of serum albumin and in chronic patients. risk predictors dialysis and a A analysis of nutritional parameters as predictors of outcome in and patients. of in for in a prospective et al . and in with patient and vascular is as as albumin in the nutritional assessment of patients. A and nutritional index patients. in and years of prospective Practice in and risk for of in patients with et al . serum albumin and outcome in dialysis et al . risk in patients by chronic of the et al . Low and risk of death in a cohort of chronic patients. A et al . of mortality in patients. et al . between level and mortality in dialysis of and malnutrition. et al . in patients. et al . protein of patients undergoing et al . body nitrogen as a in maintenance dialysis. Nutritional with renal at the start of dialysis. body nitrogen mortality in haemodialysis patients a malnutrition and as predictors of vascular and mortality in et al . body protein in haemodialysis patients. body and body in patients with chronic renal failure. Nutritional of patients an Nutritional and of in patients. of body in chronic renal of and with A to the Malnutrition for and nutritional parameters in chronic patients. of et al . than protein in chronic haemodialysis patients. global assessment of in dialysis patients. in nutritional parameters after initiation of chronic et al . in body mass in a between and rate of protein–energy malnutrition in chronic haemodialysis patients from to with an of A poor intake is the for malnutrition in patients. have reported spontaneous to be as low as some patients may well with than the dialysis should be to a minimal protein intake of intake should be with a intake to an protein intake in chronic haemodialysis patients should be at body (Evidence level III). in a chronic haemodialysis patient should be at body (Evidence level III). has been the protein intake in patients studies and their is less than to In studies nitrogen during many and body as well as level as reported in studies as a to the a of a minimal intake means that of be be by the is for patients who be in by this the a by of the to the protein intake through studies is considered it that of patients protein to their this also that half of the be to a protein intake their is the a in in nutritional status a protein intake less than the recent have increased the daily protein intake body in a recent it was to for was it to in according to the of protein Thus, a intake of quality protein and protein should be protein to be for the the dialysis a loss of and through the dialysis which may be more in to the of more more as the dialysis is a catabolic for protein of of of in to the decrease in at the start of the haemodialysis in to an and catabolic may to the patients during the dialysis through has been shown to this catabolic and should be as as have during the the catabolic may be present be by an [19]. intake may according to the dialysis intake was greater by on than on dialysis an by et al . a dialysis intake was reported to be by on the of the in to well with the from et al . that patients with a had a of as with who had an to a of data in dialysis patients that in studies in chronic dialysis patients, a protein intake of less was associated with a protein intake g/kg/day patients have many to a level of protein intake of of nutritional in renal have by nutritional status in patients less protein may have been in patients, and for the of protein intake should be recommended for the dialysis In a of more than haemodialysis patients, et al . that serum albumin a of for a of serum albumin were in patients with greater data have been from prospective studies et al . reported in patients that body as assessed by was with a level of protein intake of and that was for the patients more than and a of protein intake for each in haemodialysis patients in nutritional parameters between the which were in of intake In a analysis of the study, serum albumin was shown to be associated with protein intake by normalized between and on serum albumin for a protein may nutritional may be associated with in a prospective of more than chronic haemodialysis patients in higher was associated with higher by analysis the group reported increased in patients with an between and as with the an than was in the quartile of patients protein and In recent prospective study, et al . reported an between and mortality hospitalization rate in patients (Kt/V protein from an increase in which has some to a increase in vascular have the of in and well renal in an to dialysis is however, the between and is less and

Abstract: We review the physics opportunities of the Future Circular Collider, covering its e+e-, pp, ep and heavy ion programmes. We describe the measurement capabilities of each FCC component, addressing the study of electroweak, Higgs and strong interactions, the top quark and flavour, as well as phenomena beyond the Standard Model. We highlight the synergy and complementarity of the different colliders, which will contribute to a uniquely coherent and ambitious research programme, providing an unmatchable combination of precision and sensitivity to new physics.

Abstract: In response to the 2013 Update of the European Strategy for Particle Physics (EPPSU), the Future Circular Collider (FCC) study was launched as a world-wide international collaboration hosted by CERN. The FCC study covered an energy-frontier hadron collider (FCC-hh), a highest-luminosity high-energy lepton collider (FCC-ee), the corresponding 100 km tunnel infrastructure, as well as the physics opportunities of these two colliders, and a high-energy LHC, based on FCC-hh technology. This document constitutes the third volume of the FCC Conceptual Design Report, devoted to the hadron collider FCC-hh. It summarizes the FCC-hh physics discovery opportunities, presents the FCC-hh accelerator design, performance reach, and staged operation plan, discusses the underlying technologies, the civil engineering and technical infrastructure, and also sketches a possible implementation. Combining ingredients from the Large Hadron Collider (LHC), the high-luminosity LHC upgrade and adding novel technologies and approaches, the FCC-hh design aims at significantly extending the energy frontier to 100 TeV. Its unprecedented centre of-mass collision energy will make the FCC-hh a unique instrument to explore physics beyond the Standard Model, offering great direct sensitivity to new physics and discoveries.